Reading, United Kingdom

Michael Dawson

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 6.7

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michael Dawson: Innovator in Polymyxin Compounds

Introduction

Michael Dawson is a notable inventor based in Reading, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of polymyxin compounds. With a total of 3 patents to his name, Dawson's work focuses on innovative methods for treating bacterial infections.

Latest Patents

Dawson's latest patents include groundbreaking inventions related to polymyxin compounds. One of his notable patents, titled "Polymyxin compounds and uses thereof," provides a compound of formula (I) and its application in treatment methods for bacterial infections. This invention outlines the preparation methods for the compound and specifies the structural requirements for the amino acid residues involved. Another patent in this area emphasizes the pharmaceutical compositions comprising these compounds and their use in treating microbial infections.

Career Highlights

Throughout his career, Michael Dawson has worked with several prominent companies in the pharmaceutical industry. Notable among these are Spero Therapeutics, Inc. and New Pharma Licence Holdings Limited. His work in these organizations has contributed to advancements in medical treatments and drug development.

Collaborations

Dawson has collaborated with various professionals in his field, including Pamela Brown and Mona Simonovic. These partnerships have facilitated the exchange of ideas and fostered innovation in his research endeavors.

Conclusion

Michael Dawson's contributions to the field of polymyxin compounds highlight his role as an influential inventor. His patents and collaborations reflect a commitment to advancing medical treatments for bacterial infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…